Introduction
Chronotherapy with medication involves the tailored timing of doses to match the body's natural daily rhythms and behavioral patterns in order to increase beneficial effects and/or minimize any adverse medication effects across the day and night. The daily patterns of behaviors, including the sleepwake, rest-activity, and fasting-feeding cycles, influence the daily fluctuations of gastric pH, gastric emptying, gastrointestinal transit time, organ blood flow, liver enzyme activity, and renal function [1] [2] [3] [4] . The extent to which the internal circadian system also orchestrates these physiological variations is not well understood, although likely to be an important factor that interacts with these daily patterns of behaviors [5] . The sum of these daily circadian (24-h) and behavioral physiological patterns can therefore affect a medication's bioavailability and duration of action through absorption, distribution, metabolism, and elimination. A medication's effects are also dependent on receptor site availability and function [6] , which can also be affected by the circadian system and by prior behaviors, such as exercise [4] . Currently, very few medications are administered based on the time of day in order to optimize beneficial effects or reduce side effects. Moreover, internal biological time (circadian phase) can differ between people in relation to external clock time [7] , yet, since it is difficult to instantaneously assess circadian phase, there are virtually no medications currently administered based on internal biological time. However, recent examination of 12 different organs in a mouse model demonstrates that the protein targets of 56% of the top-selling and World Health Organization essential medicines oscillate with circadian profiles [8] . This suggests that chronotherapy, either in terms of external clock time or internal biological time, is underutilized and could be a major consideration to improve modern personalized medicine.
This article is part of the Topical Collection on Sleep and Hypertension
Hypertension (HTN) is a primary risk factor for adverse cardiovascular (CV) events [9] . Given the well-documented 24-h pattern of arterial blood pressure (BP) in humans, with a morning surge and a decrease during sleep [10] , as well as the recognition of increased risk for adverse CV events in the morning [11] , chronotherapy for HTN has actually been studied since the late 1980s. According to the recent 2017 American College of Cardiology and American Heart Association guidelines for prevention and treatment of HTN [12] , the prevalence of HTN among US adults is 46%. Although almost three quarters of these adults use antihypertensive medications, only half maintain their mean BP at an acceptable level [9] . Thus, improvement in therapy for HTN is warranted, and chronotherapy offers great promise in this regard. BP usually increases during daytime activities and decreases (~10-20%) during nocturnal sleep [13, 14] . The degree to which BP rises or falls during sleep and daytime behaviors, measured using 24-h ambulatory BP monitoring (ABPM), is associated with varying risk for all-cause mortality [15] , CV events [16] , and stroke [17, 18] . Based on 24-h profiles of BP, people with HTN can be broadly classified into four patterns: the (1) normal healthy dipping BP (10-20% drop in average nocturnal vs. daytime BP); (2) extreme-dipping (> 20% drop in average nocturnal vs. daytime BP); (3) nondipping BP (< 10% drop in average nocturnal vs. daytime BP); and (4) reverse dipping (average nighttime BP is higher than daytime BP [19, 20] ). A non-dipping BP profile, prevalent in 32-46% of adults with HTN [21] , is associated with impaired cardiac function including increased left atrial systolic volume and left ventricular wall thickness, and lower right atrial ejection fraction [22] [23] [24] . Non-dipping BP is also associated with numerous chronic conditions including autonomic dysfunction [25] , renal insufficiency [26] , glucose intolerance [27] , and obstructive sleep apnea [28] . Although less common, reverse dipping BP, prevalent in 5-19% of adults with HTN [21] , is associated with severe renal dysfunction, CV injuries, carotid plaque formation, and lacunar infarction in hypertensive patients [29] [30] [31] . Patients with extreme dipping BP, prevalent in 4-20% of adults with HTN [21] , have an increased risk of silent cerebral infarcts [18] . Additionally, a meta-analysis suggests that among patients who are untreated at baseline, extreme dippers have an increased risk of total CV events compared to normally dipping hypertensive patients [21] .
Altered dipping profiles could conceivably be caused in some people by altered behaviors, such as decreased nocturnal sleep raising the nocturnal BP or reduced daytime activity lowering the daytime BP [19, [32] [33] [34] , both of which would tend towards a non-dipping profile. Pharmacological approaches to improve sleep quality convert only a subset of the non-dipping population into dippers [35] , which suggests that the dipping vs. non-dipping is not simply caused by differences in sleep. Despite the association between the degree of day/night BP fluctuation and the risk for adverse CVevents, it remains unclear whether this risk is a result of the decline of BP over the course of a night, low nighttime BP, or the surge of BP upon awakening. Nevertheless, a number of studies have investigated the impact of morning vs. evening dosing of antihypertensive medications on BP dipping profile, 24-h BP control, BP decline during sleep, and/or the reduction of a morning BP surge. Studies conducted from 1987 to 2012 are briefly discussed immediately below, whereas this review will focus on research published in the 5-year period from 2013 to 2017. As previously reviewed in 2010 [36] , evening compared to morning ingestion of the common classes of antihypertensive medications generally enhances their BP-lowering effects, these include alpha-adrenoceptor blockers (α-blockers [37] [38] [39] ); beta-adrenoceptor blockers (β-blockers [40] ); angiotensin-converting enzyme inhibitors (ACEI [41] [42] [43] [44] [45] [46] [47] [48] [49] ); angiotensin II receptor blockers (ARB, [50] [51] [52] [53] [54] ); diuretics [55, 56] ; and calcium channel blockers (CCB, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] ). Interestingly, although a low-dose of aspirin (100 mg/day) has traditionally been used as an anticoagulant to prevent CV events [69] , when administered at bedtime but not in the morning, it has also been shown to reduce ambulatory systolic BP (SBP) and diastolic BP (DBP) [70] [71] [72] . The authors speculate that these findings are related to aspirin's ability to inhibit angiotensin II in a circadian fashion. Additional open-label prospective randomized control trials (RCT) conducted by Hermida and colleagues, including the MAPEC (Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events) study with a total of 2156 hypertensive subjects and a median follow-up of 5.6 years, have consistently shown that by targeting the nocturnal rise in BP there is overall improved 24-h BP control, decreased morning BP surge, decreased prevalence of non-dipping BP, reduced CV morbidity, and improved survival [73] [74] [75] .
The recent studies reviewed herein extend the above findings by purposefully examining fixed-dose combination therapy, which is generally considered the first line of treatment in individuals with severe HTN (> 180 mmHg SBP and/or > 110 mmHg DBP) [76] [77] [78] . Further, recent studies have examined the co-occurrence of HTN with diseases including obstructive sleep apnea, chronic kidney disease, and diabetes. Disease comorbidity may alter underlying physiology including the circadian rhythms of drug targets, necessitating additional examination of any potential benefit or risk of chronotherapy. Moreover, despite the compelling evidence of examined RCTs to date including the comprehensive cardiovascular disease (CVD) and end-organ damage outcomes reported from the MAPEC cohort, routine clinical care in most countries continues to predominately utilize a morning antihypertensive dosing strategy. Physicians generally prescribe multiple medications at increasing doses for individuals with difficult to treat or severe HTN [76] [77] [78] . An increased medication load increases the incidence of unwanted side effects and may decrease a patient's adherence to their intended drug regimen [79, 80] . It seems likely that adverse medication side effects and the number of prescribed medications could be reduced by simply considering the timing of doses relative to the naturalistic rise and fall of BP and regulators of BP.
Methods
An extensive search of the literature was conducted in December 2017 to identify publications regarding the treatm e n t o f H T N t h a t a l s o f o c u s e d o n t h e u s e o f chronotherapeutic principles, namely time of day. PubMed, Google Scholar, and Scopus were used to search for the following keywords and their combinations: "chronotherapy" AND "hypertension"; "chronotherapy" AND "high blood pressure"; "night time" AND "dosing" AND "hypertension"; "evening dosing" AND "hypertension"; "bed time" AND "dosing" AND "hypertension." Articles were limited to the English language and human studies, original articles including case reports, meta-analyses, and systematic reviews, while poster or talk abstracts were excluded. Publications were limited to the 5-year period from January 2013 to December 2017. Abstracts of articles were then scanned for relevance and categorized based on primary HTN (n = 14 studies), HTN with a specific comorbid conditions (OSA, chronic kidney disease, diabetes) (n = 13), meta-analysis or systematic review (n = 5), or chronopharmocology (n = 4). Results from original studies are presented in Tables 1 and 2 . These tables provide a summary of the following for each study: (1) country of origin; (2) design (e.g., crossover); (3) participant characteristics; (4) how HTN was measured and/or defined; (5) duration of follow-up; (6) class of medication and time of medication administration (i.e., morning vs. evening); (7) measured study outcomes including BP specific outcomes; and (8) study results. The tables are intended for a quick reference, but salient points and distillation of general findings are presented in the text of the "Results" section of this paper. Meta-analyses are presented at the end of each section as these include some of the other listed studies.
Results

2013-2017
Updates on the Effects of Time-Dependent Dosing for Treatment of HTN (Table 1) The first study listed in Table 1 represents a secondary analysis of the MAPEC RCT and revealed that participants with resistant HTN (suboptimal BP control with more than three antihypertensive medications) have improved ambulatory BP control, a lower incidence of CVevents, and reduced mortality over a 5-to 6-year follow-up when they took one or more antihypertensive medications at night compared to all medications in the morning [81••] . Unfortunately, the study was not powered to provide absolute conclusions on the benefit of morning compared to bedtime administration by drug class or the benefits of particular drug combinations. Three crosssectional studies exploring the efficacy of taking one or more antihypertensive medications at night indicate that bedtime antihypertensive medication reduces asleep SBP, DBP, and prevalence of non-dipping BP, and improves 24-h BP control [85, 90, 110] . A smaller RCT of ARB found no significant effects of treatment timings on morning home BP or office BP [89] . However, this study did not include overnight or sleep measures of BP and included use of various other medications concurrently. Furthermore, there was a mean difference in baseline office SBP of 5 mmHg (p = 0.052), which may have led to a negative result in this study. These results are also similar to previous work and could also be attributed to the relatively long half-life (> 12-h) of the ARB olmesartan [111] .
A systematic review conducted to evaluate the improved effectiveness of aspirin by changing the timing of administration on the primary and secondary prevention of CVD reported on 12 studies (including nine RCTs) that described outcomes of BP [112, 113••] . In general, studies that examined younger populations with untreated mild HTN or pre-HTN reported reduced 24-h SBP and DBP when aspirin was administered in the evening. Studies that examined populations with treated HTN or with established CVD had no improvements on ABPM regardless of aspirin timing [82, 88, 92] . However, bedtime administration was correlated with lower morning platelet reactivity [82] suggesting that although bedtime aspirin may have limited utility for BP control in patients with advanced HTN, it might be effective to reduce CV risk during the vulnerable morning hours [114] . It is also likely that concurrent administration of two or more drugs can affect pharmacokinetics and drug efficacy. This concept is briefly considered in the "Discussion" section.
In addition to the aforementioned studies, a number of papers have extended prior outcomes by examining the chronotherapeutic effect of antihypertensive combination therapy. Unfortunately, a large percentage of hypertensive individuals are unable to optimally control their BP despite taking two or more antihypertensive medications-although this may be related to a lack of medication adherence [77, 115] . As with monotherapy, it is possible that taking one or all of these medications at bedtime may prove to be a better therapeutic strategy. To this extent, an open-label trial examining the impact of taking all antihypertensive medications at bedtime compared to the morning resulted in improved 24-h BP control [83•] . However, trials on specific drug combinations have demonstrated mixed results. For example, analyses of BP response to morning or evening dosing of a diuretic and an ARB combination showed similarly significant reductions in the y, years morning surge of SBP as compared to baseline [86] . In patients with HTN and atrial fibrillation, combined therapy of an ARB and a CCB reduced 24-h BP, nighttime BP, pre-awake BP, morning BP, and nighttime BP variability regardless of dose timing [87] . Similarly, a non-inferiority clinical trial that compared the effect of morning and bedtime administration of an ARB and CCB combination reported that morning dosing reduced nocturnal brachial and central SBP and DBP whereas bedtime dosing only reduced nocturnal central DBP [84] . This was the first chronotherapy study to report central aortic BP, which the research group estimated from brachial pulse wave non-invasively using an oscillometric ABPM. Consistent findings of equivalent effects on nocturnal brachial BP reduction with ARB and CCB combination therapy may reflect the long-acting properties of these medications when taken concomitantly [116, 117] . Most patients treated for HTN receive once-daily regimens (monotherapy or combination therapy) as a result of the therapeutics' 24-h efficacy or in an effort to increase treatment adherence [80] . Yet despite the long terminal half-life of, for example, the ARB telmisartan (~24 h [118] ), Hermida et al. report additional benefits of taking the drug at night including increased nighttime sleep decline of BP [53] . The group has presented similar findings related to olmesartan (ARB) which has a terminal half-life of~13 h [52, 118] . In contrast, Ushijima et al. [93] report no additional benefit of taking olmesartan in the evening compared to the morning. Moreover, the study confirms decreased BP during sleep when valsartan (ARB with terminal half-life of 6 to 9 h) is taken at bedtime compared to the morning [93, 118] . Thus, it is surprising that Zappe et al. conclude that once-daily administration of valsartan resulted in similar 24-h BP control regardless of dosing time and when compared to administration of a long-acting ACEI taken in the morning [94••] . In contrast, Szauder et al. report that twice-daily administration of an ACEI or an ARB was more effective in converting nondippers to dippers compared to once-daily dosing of either medication in the evening [92] . The latter study suggests that for some drug classes, twice-daily dosing may be required to obtain ideal BP control.
Finally, the meta-analysis shown at the end of Table 1 compared five clinical trials that administered antihypertensive medications in the evening compared to 170 clinical trials with dosing in the morning, and reported a significant 48% reduction in relative risk of adverse CV events in patients ingesting their medications in the evening compared to that in the morning [95••] . Thus, regardless of the complexities of the varied studies, the different sizes, study designs, and patient groups in the studies, and the different degrees of HTN and of non-dipping BP, it seems possible to make the general conclusion that evening dosing of antihypertensive medication is not harmful and yet may be highly beneficial to important clinical outcomes in the general population with HTN.
More studies are needed to determine the specific mechanisms and the specific medications that provide this benefit. The next section examines the same question, but in populations with HTN and other specific comorbidities.
Chronotherapy in Comorbid Populations
Comorbid conditions are more common in people with HTN compared to those who are normotensive [119] . It has been recommended that management of any comorbidity should be directed at both the underlying condition as well as lowering BP, with awareness for possible drug interactions and adverse side effects [77] . However, current treatment regimens successfully control BP levels in fewer than half of comorbid HTN participants, which likely contributes to the increased incidence of CVD and stroke in patients with HTN and comorbidity [119, 120] . Furthermore, the study of therapy for HTN in the presence of additional disease is important because medications rarely have simple linear additive effects, such that interactions between treatment for comorbid conditions may greatly alter (attenuate or enhance) the effects of antihypertensive medications [121] . Adding the dimension of timed medication therefore increases complexity but more understanding of the extent and direction of such interactions could reveal opportunities for even better therapy both for HTN and any underlying comorbidity.
Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) can be a secondary cause of HTN independent of age, sex and obesity status [77, [122] [123] [124] [125] . Prospective epidemiological studies have demonstrated a robust dose-dependent association between OSA at baseline and the prevalence and incidence of HTN [126] [127] [128] . Continuous positive airway pressure (CPAP) therapy can lower the risk of HTN [129] . However, due in part to low longterm adherence to CPAP therapy, meta-analyses indicate that CPAP therapy for OSA results in only small (1-2 mmHg) average reductions in BP [130] [131] [132] -levels not sufficient to bring HTN under control nor large enough to reduce risk of stroke or coronary heart disease [133] . Treatment with antihypertensive drugs yields larger long-lasting reductions in BP in populations with OSA who do not use CPAP [134] [135] [136] , but these drugs fail to generate the reductions obtained in HTN patients without OSA [137] . Moreover, standard antihypertensive treatment does not bring BP under control in people with severe OSA [138] and requires the addition of CPAP to achieve reductions in both daytime and nocturnal SBP [139] . Of further concern, non-dipping BP occurs in 48-84% of patients with OSA [28, [140] [141] [142] , possibly related to the associated hypoxia-and hypercapnia-induced sympathetic activity and subsequent vasoconstriction [143] . Arousal ends the upper airway obstruction and with this arousal and upon resumption of breathing, cardiac output increases in conjunction with constricted peripheral vasculature resulting in increased BP. This can happen hundreds of times per night. Recurrent activation of this pathway can lead to daytime persistence of HTN [144] . These maladaptations may actually account for improved efficacy of β1-adrenergic blockers in older hypertensive OSA patients [145] .
Nocturnal medication dosing may improve BP control in the absence of CPAP adherence in patients with nocturnal HTN [146] , non-dipping BP [147] [148] [149] , or resistant HTN, as discussed below. Table 2 summarizes five original studies and one meta-analysis of the effects of time-dependent dosing for treatment of HTN in patients with HTN and OSA. Generally, these studies demonstrate that nighttime dosing of an antihypertensive medication improves BP control in OSA. Specifically, a prospective study comparing administration of an ARB alone or combination of an ARB and CCB demonstrated a greater reduction of both nighttime SBP and DBP and increased dipping BP as a result of evening compared to morning dosing irrespective of CPAP use [98•] . A retrospective analysis of an observational study also revealed that addon nocturnal treatment with a CCB among patients with OSA resulted in a distinct reduction of both mean nighttime SBP and DBP and an increased dipping BP pattern independent of CPAP treatment [96] . Finally, in a case study, bedtime dosing of an α1-blocker suppressed exaggerated hypoxia-triggered nocturnal SBP surges, as well as the early-morning SBP surge [100] . This report was unique in its use of a trigger sleep BP (TSP) monitoring system that takes a BP measurement when a patient's oxygen desaturation falls below a set threshold that is monitored continuously by pulse oximetry. This method allows researchers to assess the BP surge associated with an apnea/arousal cycle [150] , and may be a useful addition to any study of the effectiveness of antihypertensive medication in OSA. The TSP monitoring method was also employed in a crossover study comparing the effect of nighttime dosing of a CCB vs. a non-selective β1/2-adrenergic receptor blocker [97••] . This prospective study demonstrated that a nighttime single-dose administration of both medications resulted in a pronounced reduction of the mean sleep SBP and the hypoxiarelated peak sleep SBP in HTN patients with OSA. Unfortunately, the latter study did not compare these effects to morning dosing.
In contrast to the above studies, a RCT in patients with moderate to severe OSA and HTN showed that an ACEI taken at night did not further reduce nocturnal SBP compared with morning dosing (− 6.9 mmHg, − 8.0 mmHg, respectively), regardless of the addition of CPAP, which similarly lowered sleep SBP both with morning and evening dosing [99] . Morning compared to evening administration of the ACEI was also superior at reducing daytime SBP. Neither morning nor evening ingestion improved the rates of non-dipping BP.
Finally, the meta-analysis shown at the end of the OSA section in Table 2 presents the combined result of 3582 patients and revealed that evening compared to morning antihypertensive medications in OSA result in significantly reduced nocturnal SBP and DBP, as well as reduced non-dipping BP profiles. These results are therefore similar to the results in the general population (Table 1) , but conflicting results between the prospective RCT and smaller mixed designed studies emphasize the need for additional rigorously run studies among a diverse population of OSA patients.
Chronic Kidney Disease
Chronic kidney disease (CKD) is considered an accelerator of CVD and an independent risk factor for adverse CV events [151] . CV risk increases inversely to the estimated glomerular filtration rate (eGFR) and all stages of CKD are associated with increased risks of CV morbidity, premature mortality, and/or decreased quality of life [152] [153] [154] [155] . CKD is often classified into five stages using thresholds of serum creatinine, eGFR, and/or evidence of structural renal changes such as proteinuria [156] . A systematic review and meta-analysis in 2016 estimated the global CKD prevalence to be 11-13% with prevalence by severity: CKD stages 1 to 5, 13.4%; and stages 3 to 5, 10.6% [157] . HTN is the most common comorbidity in patients with CKD with the prevalence of HTN increasing with declining renal function [158, 159] . Although elevated BP can occur as a result of CKD, increased BP is also a risk factor for severe CKD [160] . Therefore, control of HTN is a medical priority in the management of CKD and offers an opportunity to slow further loss of kidney function [161, 162] . Additionally, optimal HTN control in CKD helps prevent end-organ damage, notably in the heart and brain [161, 163, 164] . ABPM in patients with CKD often reveals elevated nocturnal BP [165, 166] with non-dipping increasing risk of total mortality or end-stage renal disease [167] . However, to date, studies that consider chronotherapy in CKD patients are limited and with mixed effects. Two systematic reviews conducted between 2013 and 2017 suggest that administration of antihypertensive medications in the evening should be considered for CKD patients with HTN to lower nighttime SBP and/ or DBP [109••, 168] , reduce non-dipping BP [109••] , and prevent adverse CV events and mortality [168] . Table 2 summarizes four original studies of the effects of time-dependent dosing for treatment of HTN in patients with HTN and CKD. A cross-sectional study (also included in the systematic reviews mentioned above) demonstrated that ingestion of one or more antihypertensive medications at night in participants with mild HTN and CKD was associated with lower asleep SBP and DBP [101] . Thus, the prevalence of non-dipping BP was attenuated when at least one antihypertensive medication was taken at night, and was further decreased when all medications were ingested at night. In a pilot RCT, participants Non-dipping BP defined as average nocturnal SBP reduction compared to average awake SBP (measured using ABPM) ≥ 0% but < 10%; extreme dipper nocturnal SBP reduction ≥ 20%; and riser or reverse dipper when reduction < 0%.
ABPM, ambulatory blood pressure monitoring; ACEI, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin II receptor blocker;
BP, blood pressure; CCB, calcium channel blockers;
CKD, chronic kidney disease;
CVD, cardiovascular disease; DBP, diastolic blood pressure;
EF, ejection fraction; ESS, Epworth sleepiness scale;
HF, heart failure; HTN, hypertension; MI, myocardial infarction;
OSA, obstructive sleep apnea; RAAS, renin-angiotensin aldosterone system; RASI, renin-angiotensin system inhibitor;
RCT, randomized controlled trial;
SBP, systolic blood pressure; T2D, type 2 diabetes mellitus;
TSP, trigger sleep BP; y, years with non-dipping BP and CKD who received an ARB at bedtime, demonstrated not only decreased nighttime BP but also improved renal and CV protection (i.e., slower decline in eGFR, decreased proteinuria, and better target organ protection [107] ). A smaller observational study suggested that morning and evening administration compared to morning dosing alone resulted in similar effects on office BP and morning home BP [105] . However, the study did not measure BP across the night and was therefore unable to account for potential benefits related to the prevalence of non-dipping BP. We note that various regulators of renal function exhibit circadian fluctuations including glomerular filtration rate in humans [169] , as well as sodium excretion and renal blood flood in rodent models [170] . Thus, the kidney is highly relevant to daily fluctuations in pharmacodynamics and potential responsiveness to medications. For instance, the kidneys are vital sources and targets of hormones that regulate BP including angiotensin II, aldosterone, vasopressin, angiotensinconverting enzymes, and plasma renin activity all of which exhibit circadian rhythms in rodent models [171] [172] [173] . Thus, by considering these factors, there ought to be great potential for the use of chronotherapy to take advantage of rhythm peaks and troughs that could lead to superior BP control and reduced side effects in patients with CKD. However, overall, the results in CKD are somewhat similar to the results in the general population (Table 1) showing some benefit in terms of increasing dipping profile by reducing nocturnal BP more than daytime BP, but there are fewer studies and so far no hard CV outcomes such as incidence of serious adverse CV events in the specific trials of timed antihypertensive medications in CKD. This therefore remains an important area for further research. Moreover, also included in Wang and colleague's meta-analysis of CKD and HTN is the only study to our knowledge that has specifically studied individuals of African descent [103••] . The study found only modest nonsignificant reductions in nocturnal BP with either evening schedule compared to morning dosing. This all-Black study population took on average four antihypertensive medications and~75% had non-dipping or reverse dipping BP. Thus, there appears to be an interaction between race/ethnicity and time of medication to control HTN in CKD. Therefore, there is an urgent need for additional prospective randomized studies that focus on minority populations that are at increased risk for end-stage kidney disease [159, [174] [175] [176] .
Diabetes
Hypertension is often a comorbid condition with both type 1 and type 2 diabetes [177] . Microvascular and macrovascular dysfunction (retinopathy, neuropathy, nephropathy, increased predisposition to atherosclerosis, etc.) and ultimately an adverse CV event or death are more prevalent in people with diabetes who also have HTN than in those without HTN [177, 178] . Patients with type 2 diabetes usually exhibit overt HTN upon initial detection of microalbuminuria [179] . Patients with type 1 diabetes often do not present with elevated office BP even in the presence of microalbuminuria which is an early indicator of nephropathy [180] . However, ABPM reveals that individuals with type 1 diabetes and microalbuminuria have higher nocturnal BP and an increased prevalence of non-dipping BP compared to those with type 1 diabetes and a normal urinary albumin excretion, and this lack of BP dipping with type 1 diabetes and microalbuminuria could be the result of a lack of sympathetic withdrawal during sleep [180] [181] [182] [183] [184] [185] . Prospectively, it has been demonstrated that an increase of nocturnal SBP over the course of 5 or more years can precede the development of microalbuminuria [186] . Taken together, these findings highlight the necessity for use of ABPM to avoid the underdiagnosis of HTN in type 1 diabetes, and the logical potential for chronotherapy for HTN in individuals with type 1 diabetes. Type 2 diabetes and HTN increase CV risk by common physiological pathways (i.e., obesity, insulin resistance, hyperglycemia, decreased nitric oxide [177] ) with each disease state possibly exacerbating the other. For instance, hyperinsulinemia increases sympathetic activity, and hyperglycemia activates the renin-angiotensin system [177] , which in itself may be a mechanism for increased risk of diabetes in HTN [187, 188] . Further, individuals with type 2 diabetes are more likely to exhibit a non-dipping BP or reverse dipping BP phenotype [189, 190] . Thus, chronotherapeutic treatment strategies that target nighttime BP among people with type 1 or type 2 diabetes ought to be seriously considered. Table 2 summarizes four recent original studies of the effects of time-dependent dosing for treatment of HTN in patients with diabetes. At present, there is only one published study investigating morning compared to evening dosing of antihypertensive medications in individuals with type 1 diabetes. This report suggests that bedtime dosing of an ACEI in patients with CV autonomic neuropathy increased nighttime BP dipping [107••] . A cross-sectional study in participants with type 2 diabetes reported bedtime medication administration was a positive predictor for a normal dipping BP pattern and that CCBs and β-blockers were more likely to be administered at bedtime than in the morning [105] . In a prospective open-label trial of participants with type 2 diabetes and high nocturnal BP, bedtime compared to morning dosing reduced both nighttime and 24-h SBP and DBP [108•] . However, bedtime dosing in this population did not decrease daytime SBP and DBP and the morning SBP surge did not differ between morning and bedtime dosing. Similar results were published from post hoc analysis of individuals with type 2 diabetes in the prospective MAPEC study [74] . Additional analysis of the MAPEC cohort demonstrated that dosing of at least one antihypertensive medication at bedtime, particularly those acting to regulate angiotensin II signaling, resulted in not only improved ABPM control, but also a reduced risk of new-onset diabetes [106••] . Evidence available thus far suggests that nocturnal dosing of medications helps in reduction of nocturnal BP and controlling morning surge in BP and is at least as good as daytime medication for CV outcomes. Studying the antihypertensive effects of medications prescribed at different times of the day holds promise and should be followed through by conducting prospective randomized controlled blinded clinical trials with solid morbidity and mortality outcomes. Such a trial, the Hygia Project-a multicenter study in Spain conducted from 2007 to 2015-aims to extend the current body of knowledge to investigate if treatment-induced changes to ABPM reduce risk of CVD events, stroke, newonset diabetes, and/or CKD in a primary care setting [191•] .
Discussion
Research conducted from 2013 to 2017 generally demonstrates improved 24-h BP profiles, and more dipping BP profiles, with at least one medication taken in the evening. In most cases, these findings persist regardless of medication class or disease comorbidity. The incorporation of nocturnal BP averages as either study inclusion criteria or as a study outcome points to the increased recognition for the need to improve nocturnal BP dipping rather than simply avoiding diurnal BP surges. Among studies that report no difference between morning and evening dosing of antihypertensive medications, none report significant increases of nocturnal hypotension, unwanted side effects, or increased nonadherence to medication schedule. Thus overall, these results suggest that taking medication in the evening should be endorsed in most cases. This decision can be made because of the potential for benefit (especially for nocturnal BP and improved dipping status, and in some cases overall 24-h BP, and in some cases hard clinical CV outcomes), and without increase in harm. However, beyond this general recommendation, it should be noted that in addition to receiving an antihypertensive medication at bedtime, many of the participants in studies that reported improved benefit with nocturnal dosing also continued to receive morning medications. For example, in the MAPEC trial, participants moved one or more drugs to the evening, but continued to take the remainder of their medications in the morning [73] . Additionally, although less transparent, participants in HTN studies with a comorbid disease are likely taking additional non-antihypertensive medications in the morning such as glucagon-like peptide 1 (GLP-1) receptor agonists for the treatment of type 2 diabetes. GLP-1 receptor agonists have been shown to decrease both SBP and DBP [192] , thereby potentially impacting BP control independently or synergistically with antihypertensive medications as further discussed below. Therefore, a refined recommendation and simplified general rule may be to split medication dosing between the evening and morning. Moving forward, chronotherapy as it pertains to HTN could be further advanced by improving study design and developing a clearer understanding of the physiological mechanism(s) that contribute to the cause and effect of altered BP dipping profiles. Both concepts are discussed below.
RCT Study Design
Many of the reviewed studies used small sample sizes despite also applying complicated study designs. As a result, studies may lack sufficient power for firm conclusions and perhaps more importantly are unable to generalize their findings. The latter is particularly the case in terms of racial, ethnic, and gender diversity. This may be a particular concern for Americans, yet of the reviewed studies, only one was conducted in the USA. To that extent, Black compared to White Americans have an earlier incidence of CVD, more difficulty in controlling their HTN, and an increased prevalence of nondipping BP [193] [194] [195] [196] [197] [198] [199] [200] [201] . The racial differences in HTN cannot be attributed to differences in awareness or treatment-reported to be increased among Blacks compared to Whites, nor the use of non-pharmacological therapy, lack of health-insurance, economic barriers, or access to healthcare [194, [202] [203] [204] [205] . Furthermore, Black Americans have an increased burden of end-stage renal disease despite the larger prevalence of CKD among White Americans [159, [174] [175] [176] . Middle-aged Black compared to White Americans are also at a greater risk of developing type 2 diabetes and have higher BP prior to the development to diabetes [206] [207] [208] . The increased prevalence of these traditional CV risk factors in Blacks likely require additional strategies to promote equitable CV outcomes as noted in a 2017 American Heart Association Scientific Statement [209••] . Similarly, women have generally been underrepresented in relation to their burden of disease in RCTs of CVD prevention [210, 211] . As highlighted in a review by Tamargo et al., women present differences in body composition, physiology, pharmacokinetics, and pharmacodynamics that may impact their response to antihypertensive medications [212••] . Women may have different endogenous circadian rhythms compared to men [213, 214] . Although it remains unclear how these differences between genders in circadian rhythms may impact regulators of BP, these differences highlight the need for increased inclusion of women in RCTs in order to better inform evidence-based treatment regimens. In light of these differences, RCTs examining the time of day that antihypertensive medications are administered could benefit from improved study design with clear statements on a priori power calculations and study populations with distributions that more accurately represent their disease prevalence.
Before endorsing the routine administration of antihypertensive medications at night there is also a need for additional RCTs with long-term study outcomes. The largest prospective, RCT, open-label study outside of the MAPEC trial, the Treatment In Morning versus Evening (TIME) study is currently underway in the UK [215, 216] . The trial is expected to run for 5 years with a primary end point of hospitalization for a non-fatal myocardial infarction, non-fatal stroke, or any vascular death determined by record-linkage. The TIME study (unlike the MAPEC study) has been prospectively powered and complete details of the study's randomization process have been published [216] . Unfortunately, this British-led study may continue to lack the study diversity necessary to generalize global dosing guidelines.
Physiology and Mechanisms of BP Dipping
Despite being a clear target for recent RCTs, the mechanism(s) that contribute to altered BP dipping profiles remain elusive and provide a continual challenge for developing an ideal medication schedule. A clearer understanding of the mechanisms driving the daily rhythms of BP, and ultimately matching classes of medications to the rhythms of their drug target, may result in improved BP control. More precisely, it would seem a promising endeavor to regulate BP to a pattern that not only falls within a specific threshold, but one that mimics the daily variation in BP in healthy subjects. This increased understanding of the interactions between behavior (e.g., sleep-wake cycles, feeding) and circadian rhythms that influence BP regulation and medication bioavailability could ultimately lead to RCTs tailored to underlying circadian physiology rather than just the sleep-wake cycle. The latter is particularly important for HTN patients who work a shift schedule or among patients who experience jetlag or social jetlag [217] .
Given that BP and its primary regulators exhibit robust endogenous circadian rhythms [218] [219] [220] [221] , it follows that antihypertensive medications display a time-dependent chronopharmacokinetic and chronopharmacodynamic profile [222] . Recent developments in the field of chronopharmology are beginning to take these factors into consideration. Analysis of amlodipine, a CCB, revealed daily variations in the pharmacokinetic profile of oral amlodipine with a shorter time to maximum plasma concentration (T max ) and greater mean peak plasma concentration (C max ) after evening than morning dosing [223] . Both hypertensive and normotensive subjects demonstrated this pattern indicating increased absorption when dosed at night. Additionally, amlodipine had a longer half-life with night compared to morning ingestion. This pharmacokinetic profile correlated with reductions in SBP and heart rate following nighttime dosing, demonstrating a circadian time-dependent pharmacokinetic-pharmacodynamic relationship [223] . Based on the concept that delivery of medications should be synchronized in time to the chronobiology of targeted tissues, several groups have published strategies to engineer new drug delivery systems to appropriately time compound release to match circadian rhythms [224, 225•, 226•, 227] .
The etiology of HTN is usually multifactorial because BP regulation is under the control of multiple mechanisms, such that multiple drug therapies are sometimes needed [228] . A meta-analysis consisting of 11,000 patients and 42 clinical trials concluded that BP reduction from combination therapy is approximately five times greater than simply increasing the dose of one drug [229] . This is an important consideration for chronotherapy because the additive effects of medications need to be considered to optimally reduce BP and reduce side effects. Combination therapy in HTN is also beneficial for other comorbid disease outcomes. For instance, ARBs and ACEIs prevent the progression of CKD to a similar degree, but, a combination of the two is significantly more effective at usual doses [230] . The same combination also reduced proteinuria more than either drug alone [231] . Mechanistically, this reduction is likely because of the addition of ARB related to reduction in angiotensin II which is not achieved by ACEI alone [231] , suggesting an important synergy between medications. There are also instances where two drugs can help nullify an adverse effect of one drug taken alone. For example, when a combination of aliskiren (renin inhibitor) and hydrochlorothiazide (HCTZ) is used to treat HTN, aliskiren neutralizes the compensatory increase in plasma renin activity induced by HCTZ [232] . Another important consideration is the magnitude and duration of antihypertensive activity with different drugs. For instance, amlodipine (CCB) reduces the BP in a magnitude that is more dependent on the dose; in contrast, an ARB influences the duration, rather than magnitude of antihypertensive activity [233] . Therefore, one could speculate that a CCB would be more effective as a morning dose to reduce the daytime increases in BP induced by physical activity, whereas an ARB might be more effective as an evening medication as it would provide better control over nighttime BP and the morning BP surge. The above mentioned factors and drug interactions are perhaps most relevant in elderly patients with HTN who may be taking multiple medications due to increased comorbid states associated with aging [234] .
Conclusions and Future Directions
In the last few years, the area of chronotherapy in HTN has exploded. In general, nighttime administration of antihypertensives improved overall 24-h BP profiles regardless of disease comorbidity and did not cause increased risk, and therefore ought to be seriously considered for management of HTN in the general population as well as in HTN with certain comorbidities. Yet, only the American Diabetic Association has made such a recommendation [235] , potentially reflecting further need to conduct prospective randomized studies in large and diverse populations with preexisting comorbidities allowing for adequate statistical power to perform subgroup analyses. In addition, preclinical studies to ascertain mechanisms by which chronotherapy is beneficial could aid antihypertensive drug design and guidelines for timed administration. The field may further progress by focusing on the mechanistic basis of bedtime medication use rather than simply moving a drug from morning to bedtime dosing. For instance, the mechanisms underlying the increased CV risk due to nondipping BP are yet unclear. Furthermore, these mechanisms, which may be related to the timing of meal intake, sleep patterns, or endogenous circadian rhythms, may affect BP regulators (e.g., heart, kidney, or vasculature) differentially. The latter may require personalized medicine for individuals, such as shift workers, who often follow atypical sleep and eating patterns or the engineering of medications that optimize bioavailability and the naturalistic rhythms of drug targets. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
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